Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo
BACKGROUND: Cisplatin-based chemotherapy is the first-line treatment for ovarian cancer. However, acquired resistance to cisplatin treatment often occurs in epithelial ovarian cancer, and effective and practical methods for overcoming this obstacle are urgently needed. The study aimed to demonstrate the synergistic effect of clarithromycin (CAM) with cisplatin to inhibit ovarian carcinoma cells growth in vitro and in vivo.
RESULTS: We performed CCK-8 assay to detect apoptosis rates in response to CAM alone or in combination with cisplatin, which were further confirmed by Annexin V and PI staining methods and western blotting. Mechanistically, CAM could reduce endogenous antioxidant enzyme expression and increase the levels of reactive oxygen species (ROS) to augment the cytotoxic effect of cisplatin. Meanwhile, a tumor xenograft model in athymic BALB/c-nude mice demonstrated that CAM combined with cisplatin resulted in reduced tumor growth and weight compared with cisplatin alone.
CONCLUSION: Collectively, our results indicate that CAM works synergistically with cisplatin to inhibit ovarian cancer cell growth, which may be manipulated by a ROS-mediated mechanism that enhances cisplatin therapy, and offers a novel strategy for overcoming cisplatin therapy resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of ovarian research - 12(2019), 1 vom: 08. Nov., Seite 107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Bo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cisplatin |
|---|
| Anmerkungen: |
Date Completed 30.03.2020 Date Revised 30.03.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13048-019-0570-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303075597 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303075597 | ||
| 003 | DE-627 | ||
| 005 | 20231225112051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13048-019-0570-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1010.xml |
| 035 | |a (DE-627)NLM303075597 | ||
| 035 | |a (NLM)31703731 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Bo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2020 | ||
| 500 | |a Date Revised 30.03.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Cisplatin-based chemotherapy is the first-line treatment for ovarian cancer. However, acquired resistance to cisplatin treatment often occurs in epithelial ovarian cancer, and effective and practical methods for overcoming this obstacle are urgently needed. The study aimed to demonstrate the synergistic effect of clarithromycin (CAM) with cisplatin to inhibit ovarian carcinoma cells growth in vitro and in vivo | ||
| 520 | |a RESULTS: We performed CCK-8 assay to detect apoptosis rates in response to CAM alone or in combination with cisplatin, which were further confirmed by Annexin V and PI staining methods and western blotting. Mechanistically, CAM could reduce endogenous antioxidant enzyme expression and increase the levels of reactive oxygen species (ROS) to augment the cytotoxic effect of cisplatin. Meanwhile, a tumor xenograft model in athymic BALB/c-nude mice demonstrated that CAM combined with cisplatin resulted in reduced tumor growth and weight compared with cisplatin alone | ||
| 520 | |a CONCLUSION: Collectively, our results indicate that CAM works synergistically with cisplatin to inhibit ovarian cancer cell growth, which may be manipulated by a ROS-mediated mechanism that enhances cisplatin therapy, and offers a novel strategy for overcoming cisplatin therapy resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cisplatin-resistance | |
| 650 | 4 | |a Clarithromycin | |
| 650 | 4 | |a Combination therapy | |
| 650 | 4 | |a Ovarian cancer | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a Clarithromycin |2 NLM | |
| 650 | 7 | |a H1250JIK0A |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Xia, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Thapa, Niresh |e verfasserin |4 aut | |
| 700 | 1 | |a Gan, Lijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Chaoyang |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Ensong |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yulan |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Hongbin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of ovarian research |d 2008 |g 12(2019), 1 vom: 08. Nov., Seite 107 |w (DE-627)NLM184542146 |x 1757-2215 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2019 |g number:1 |g day:08 |g month:11 |g pages:107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13048-019-0570-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2019 |e 1 |b 08 |c 11 |h 107 | ||